Qiagen (NYSE:QGEN) Issues Q3 2026 Earnings Guidance

Qiagen (NYSE:QGEN) updated its third quarter 2026 earnings guidance on Thursday morning. The company provided EPS guidance of 0.620- for the period, compared to the consensus earnings per share estimate of 0.630. The company issued revenue guidance of $538.3 million-$543.7 million, compared to the consensus revenue estimate of $552.7 million.

Analysts Set New Price Targets

A number of equities analysts recently commented on the company. Morgan Stanley raised Qiagen from an “overweight” rating to an “overweight” rating and lifted their price objective for the stock from $40.00 to $42.00 in a research note on Tuesday, June 23rd. Barclays set a $40.00 target price on shares of Qiagen in a research report on Friday. Berenberg Bank set a $45.50 price target on shares of Qiagen and gave the stock a “hold” rating in a report on Tuesday, July 14th. TD Cowen restated a “hold” rating on shares of Qiagen in a research report on Wednesday, July 15th. Finally, Weiss Ratings lowered shares of Qiagen from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, May 29th. One investment analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Qiagen presently has a consensus rating of “Hold” and a consensus price target of $42.59.

Qiagen Price Performance

Shares of NYSE QGEN opened at $41.71 on Friday. The firm’s 50-day moving average price is $39.32 and its 200-day moving average price is $41.69. Qiagen has a 1-year low of $32.53 and a 1-year high of $57.81. The firm has a market capitalization of $8.59 billion, a P/E ratio of 21.37, a P/E/G ratio of 4.19 and a beta of 0.63. The company has a current ratio of 3.21, a quick ratio of 2.57 and a debt-to-equity ratio of 0.49.

Qiagen (NYSE:QGEN) last issued its earnings results on Wednesday, August 5th. The company reported $0.62 EPS for the quarter, beating the consensus estimate of $0.60 by $0.02. Qiagen had a return on equity of 14.24% and a net margin of 19.49%.The company had revenue of $535.04 million during the quarter, compared to the consensus estimate of $527.50 million. During the same period last year, the business posted $0.60 EPS. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. Qiagen has set its FY 2026 guidance at 2.430- EPS. Equities research analysts anticipate that Qiagen will post 2.43 earnings per share for the current fiscal year.

Qiagen Increases Dividend

The firm also recently declared an annual dividend, which was paid on Tuesday, July 14th. Shareholders of record on Tuesday, July 7th were paid a dividend of $0.35 per share. This is a boost from Qiagen’s previous annual dividend of $0.26. The ex-dividend date was Tuesday, July 7th. This represents a yield of 90.0%. Qiagen’s dividend payout ratio (DPR) is presently 18.32%.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of QGEN. Commerce Bank grew its stake in shares of Qiagen by 4.9% in the fourth quarter. Commerce Bank now owns 6,725 shares of the company’s stock worth $302,000 after acquiring an additional 314 shares during the last quarter. Private Advisor Group LLC grew its stake in shares of Qiagen by 7.1% in the third quarter. Private Advisor Group LLC now owns 5,730 shares of the company’s stock worth $256,000 after acquiring an additional 378 shares during the period. Public Employees Retirement System of Ohio raised its stake in Qiagen by 0.3% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 218,591 shares of the company’s stock valued at $9,737,000 after buying an additional 594 shares during the last quarter. Zacks Investment Management increased its position in Qiagen by 0.6% during the third quarter. Zacks Investment Management now owns 135,207 shares of the company’s stock valued at $5,996,000 after acquiring an additional 742 shares during the last quarter. Finally, Janney Montgomery Scott LLC increased its holdings in Qiagen by 16.5% during the fourth quarter. Janney Montgomery Scott LLC now owns 5,481 shares of the company’s stock valued at $247,000 after buying an additional 778 shares during the last quarter. Institutional investors own 70.00% of the company’s stock.

Qiagen Company Profile

Qiagen NV (NYSE: QGEN) is a global provider of sample and assay technologies designed to enable molecular testing in the fields of molecular diagnostics, applied testing, academic research and pharmaceutical development. The company’s solutions span the full workflow of nucleic acid and protein analysis, offering customers standardized kits, instruments and software tools that streamline the preparation, detection and quantification of DNA, RNA and proteins.

The company’s product portfolio includes nucleic acid extraction and purification systems, polymerase chain reaction (PCR) reagents and instrumentation, digital PCR platforms, next-generation sequencing (NGS) library?preparation kits and proteomics solutions.